Business Context and Reporting Period
Company: Stepan Company
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2007
Business Overview: Stepan produces intermediate chemicals used in consumer and industrial applications. Operations are divided into three segments: Surfactants (75% of sales), Polymers (22%), and Specialty Products (3%).
Key Financial Metrics
| Metric (in thousands) | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Sales | $313,004 | $289,612 |
| Gross Profit | $34,809 | $32,334 |
| Operating Income | $10,532 | $6,179 |
| Net Income | $5,687 | $3,049 |
| Diluted EPS | $0.56 | $0.31 |
| Cash and Equivalents | $4,386 | $4,999 |
| Total Debt | $148,930 | $131,164 |
| Operating Cash Flow | ($6,113) | ($11,450) |
Margins: Gross margin was approximately 11.1% in Q1 2007 compared to 11.2% in Q1 2006. Operating margin improved to 3.4% from 2.1%.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% ($23.4 million) driven by a 9% increase in sales volume and favorable currency translation ($5.8 million). Average selling prices declined 1% due to sales mix changes in North American surfactants.
- Profitability: Net income rose 87% to $5.7 million. Operating income increased 70% ($4.4 million), primarily due to a $3.0 million decrease in deferred compensation expenses and improved results in the Surfactants and Specialty Products segments.
- Segment Performance:
- Surfactants: Sales up 5%; Operating income up 20% due to higher volumes and lower overhead in North America.
- Polymers: Sales up 19%; Operating income flat (-2%) as higher raw material costs and lower North American volume offset significant gains in European operations.
- Specialty Products: Sales up 22%; Operating income up significantly due to higher volumes and a favorable mix of pharmaceutical sales.
- Debt: Total debt increased $17.7 million to $148.9 million, driven by seasonal working capital needs (receivables) and capital expenditures.
Guidance, Outlook, and Risks
- Outlook: Management expects improved results for the full year 2007, particularly from North American surfactants and European polymers. Biodiesel margins remain a concern due to high soybean oil prices, but volume and mix improvements are expected to offset this.
- Capital Expenditures: Projected at approximately $43.0 million for the full year 2007.
- Subsequent Event: On April 30, 2007, the company sold its specialty ester surfactant product line to The HallStar Company. A pretax gain of $3.5 million to $4.0 million is expected in Q2 2007.
- Environmental and Legal Contingencies: The company faces potential liabilities at 22 waste disposal sites. The estimated range of possible losses is $10.7 million to $39.8 million, with an accrued liability of $19.0 million as of March 31, 2007. A $3.0 million personal injury settlement related to the Wilmington, MA site was paid in Q1 2007.
- Risks: Fluctuations in raw material costs, foreign currency exchange rates, and the outcome of environmental proceedings.
Investor Verification Checklist
- Deferred Compensation Impact: Verify the sustainability of the $3.0 million expense reduction, which was driven by a decline in the company's stock price affecting deferred compensation plans.
- Raw Material Costs: Monitor the ability to pass through rising raw material costs, particularly in the Polymers segment (polyols) and Biodiesel operations.
- Environmental Reserves: Review the adequacy of the $19.0 million accrued liability against the wide estimated loss range ($10.7M - $39.8M) for environmental sites.
- Debt Levels: Assess the impact of the increased debt load ($148.9M) on interest coverage and liquidity, especially given the seasonal nature of working capital.
- Asset Sale Execution: Confirm the realization of the estimated $3.5M-$4.0M gain from the April 30, 2007 sale of the specialty ester surfactant line.